Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide

Kidney International

Volumn 57, Issue 1, 2000, Pages 258-264

  Ioannidis, John P A ^a,b,c,d   Boki, Kyriaki A ^a,b,c,d   Katsorida, Maria E ^a,b,c,d   Drosos, Alexandros A ^a,b,c,d   Skopouli, Fotini N ^a,b,c,d   Boletis, John N ^a,b,c,d   Moutsopoulos, Haralampos M ^a,b,c,d,e  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF IOANNINA   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d LAIKO GENERAL HOSPITAL   (Greece)

^e UNIVERSITY OF ATHENS   (Greece)

Author keywords

Cyclophosphamide; Lupus nephritis; Systemic lupus erythematosus

Indexed keywords

CYCLOPHOSPHAMIDE;

ADULT; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CHRONICITY; FEMALE; HUMAN; KIDNEY BIOPSY; LONG TERM CARE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROTEINURIA; RELAPSE; REMISSION;

EID: 0034007121     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2000.00832.x     Document Type: Article

References (23)

1. 1. Berden JHM: Lupus nephritis. Kidney Int 52:538-558, 1997
2. 2. Austin HA III, Klippel JH, Balow JE, Riche NGH, Steinberg AD, Plotz PH, Decker JL: Therapy of lupus nephritis: Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 314:614-619, 1986
3. 3. Steinberg AD, Steinberg SC: Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 34:945-950, 1991
4. 4. Boumpas DT, Austin HA III, Vaughan EM, Klippel JH, Steinberg AD, Yarboro CH, Balow JE: Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340:741-745, 1992
5. 5. Steinberg AD, Gourley M: Cyclophosphamide in lupus nephritis. (editorial) J Rheumatol 22:1812-1814, 1995
6. 6. Bansal VK, Beto JA: Treatment of lupus nephritis: A metaanalysis of clinical trials. Am J Kidney Dis 29:193-199, 1997
7. 7. Boumpas DT, Austin HA III, Vaughan EM, Yarboro CH, KlipPel JH, Balow JE: Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide. Ann Intern Med 119:366-369, 1993
8. 8. Moroni G, Quaglini S, Maccario M, Banfi G, Ponticelli C: Nephritic flares are predictors of bad long-term outcome in lupus patients. Kidney Int 50:2047-2053, 1996
9. 9. Pablos JL, Gutierrez-Millet V, Gomez-Reino JJ: Remission of lupus nephritis with cyclophosphamide and late relapses following therapy withdrawal. Scand J Rheumatol 23:142-144, 1994
10. 10. Esdale JM, Levinton C, Federgreen W, Hayslett JP, KashGarian M: The clinical and renal biopsy predictors of long term outcome in lupus nephritis. Q J Med 72:779-833, 1989
11. 11. Austin HA, Muenz LR, Joyce KM, Antonovych TT, Balow JE: Diffuse proliferative lupus nephritis: Identification of specific pathologic features affecting renal outcome. Kidney Int 25:689-695, 1984
12. 12. Austin HA III, Boumpas DT, Vaughan EM, Balow JE: Predicting renal outcome in severe lupus nephritis: Contributions of clinical and histological data. Kidney Int 45:544-550, 1994
13. 13. Austin HA III, Boumpas DT, Vaughan EM, Balow JE: High risk features of lupus nephritis: Importance of race and clinical and histological factors in 166 patients. Nephrol Dial Transplant 10:1620-1628, 1995
14. 14. Churg J, Sobin LH: Renal Disease: Classification and Atlas of Glomerular Disease. Tokyo, Igaki-Shoin, 1982
15. 15. Kalbfleisch JD, Prentice RL: The Statistical Analysis of Failure-Time Data. New York, Wiley, 1980
16. 16. Cox DR, Oakes D: Analysis of Survival Data. New York, Chapmann and Hall, 1984
17. 17. SPSS INC.: Advanced SPSS 6.1. Chicago, 1994
18. 18. Cameron JS: What is the role of long-term cytotoxic agents in the treatment of lupus nephritis? J Nephrol 6:172-176, 1993
19. 19. Ciruelo E, De La Cruz J, Lopez I, Gomez-Reino JJ: Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide. Arthritis Rheum 12:2028-2034, 1996
20. 20. Boumpas DT, Balow JE: Outcome criteria for lupus nephritis trials: A critical overview. Lupus 7:622-629, 1998
21. 21. Ioannidis JPA, Lau J: Uncontrolled pearls, controlled evidence, meta-analysis and the individual patient. J Clin Epidemiol 51:1709-1711, 1998
22. 22. Balow JE, Austin HA, Muenz LR, Joyce KM, Antonovych TT, Klippel JH, Steinberg AD, Plotz PH, Decker JL: Effect of treatment on the evolution of treatment abnormalities in lupus nephritis. N Engl J Med 311:491-496, 1984
23. 23. Boletis JN, Ioannidis JPA, Boki KA, Moutsopoulos HM: Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis. Lancet 354:569-570, 1999